Theravance Biopharma (TBPH) Enterprise Value (2014 - 2026)

Theravance Biopharma (TBPH) has reported Enterprise Value for 13 consecutive years, with -$394.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 201.61% year-over-year to -$394.7 million; the TTM figure through Mar 2026 stood at -$394.7 million (down 201.61% YoY), while the FY2025 annual figure was -$315.4 million, down 256.94% from the prior year.
• Enterprise Value fell to -$394.7 million in Q1 2026 per TBPH's latest filing, from -$315.4 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$88.4 million in Q4 2024 and bottomed at -$486.8 million in Q3 2022.
• Historically, Enterprise Value has averaged -$213.2 million across 5 years, with a median of -$147.5 million in 2022.
• Annual changes were most pronounced in 2023 — Enterprise Value surged 72.47% — and 2025, when it tumbled 260.85%.
• Theravance Biopharma's Enterprise Value stood at -$327.5 million in 2022, then soared by 68.72% to -$102.4 million in 2023, then climbed by 13.74% to -$88.4 million in 2024, then sank by 256.94% to -$315.4 million in 2025, then decreased by 25.15% to -$394.7 million in 2026.
• Business Quant data shows TBPH's Enterprise Value at -$394.7 million in Q1 2026, -$315.4 million in Q4 2025, and -$329.7 million in Q3 2025.